The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not effect progression-free or overal survival

Abstract

BACKGROUND.: Studies have suggested that erythropoietin-stimulating agents (ESAs) may effect progression-free survival (PFS) and overall survival (OS) in a variety of cancer types.